85%Confidence
0Views
FDASource
2026-04-10Date
Summary
Chiesi USA's Class II recall for CUROSURF due to sterility concerns affects a critical neonatal respiratory drug, posing significant patient safety risks and potential liability. This could damage Chiesi's reputation in the specialty pharmaceutical market and invite regulatory scrutiny on their manufacturing processes.
Actionable: Assess alternative surfactant therapies like Survanta from AbbVie as Chiesi addresses this recall.
AI Confidence: 85%
Data Points
firmChiesi USA, Inc.
classificationClass II
statusOngoing
distributionNationwide within the United States
productCUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now